A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms inTandem3
- Sponsors Lexicon Pharmaceuticals
- 04 Aug 2017 This trial has been completed in Belgium (end date: 18 Apr 2017).
- 06 Jul 2017 This study has been completed in Slovakia (on 2017-04-18) according to European Clinical Trials Database record.
- 06 Jul 2017 This study has been completed in Bulgarian (on 2017-04-18) according to European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History